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O B J E C T I V E S The aim of this feasibility study was to evaluate [18F]-2-Fluoro-A85380 for in vivo
imaging of arterial nicotinic acetylcholine receptors (nAChRs) in humans. Furthermore, potentially
different vascular uptake patterns of this new tracer were evaluated in healthy volunteers and in patients
with neurodegenerative disorders.
B A C KG ROUND [18F]-2-Fluoro-A85380 was developed for in vivo positron emission tomography
(PET) imaging of nAChR subunits in the human brain. These nAChRs are also found in arteries and seem
to mediate the deleterious effects of nicotine as a part of tobacco smoke in the vasculature. It has been
previously shown that uptake patterns of the radiotracer in the brain differs in patients with
neurodegenerative disorders compared with healthy controls.
METHOD S [18F]-2-Fluoro-A85380 uptake was quantiﬁed in the ascending and descending aorta,
the aortic arch, and the carotids in 5 healthy volunteers and in 6 patients with either Parkinson’s disease
or multiple system atrophy, respectively, as the maximum target-to-background ratio. The maximal
standardized uptake value values, the single hottest segment, and the percent active segments of the
[18F]-2-Fluoro-A85380 uptake in the arteries were also assessed.
R E S U L T S [18F]-2-Fluoro-A85380 uptake was clearly visualized and maximum target-to-background ratio
uptake values corrected for the background activity of the tracer showed speciﬁc tracer uptake in the arterial walls.
Signiﬁcantly higher uptake values were found in the descending aorta. Comparison between volunteers and
patients revealed signiﬁcant differences, with lower [18F]-2-Fluoro-A85380 uptake in the patient group when
comparing single arterial territories but not when all arterial territories were pooled together.
CONC L U S I O N S [18F]-2-Fluoro-A85380 can provide speciﬁc information on the nAChR distribution in
human arteries. Vascular nAChR density seems to be lower in patients with Parkinson’s disease or multiple
system atrophy. Once conﬁrmed in larger study populations and in the experimental setting, this approach
might provide insights into the pathogenic role of nAChRs in the human vasculature. (J Am Coll Cardiol Img
2012;5:528–36) © 2012 by the American College of Cardiology Foundation
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529therosclerosis is one of the leading causes of
morbidity and mortality (1). Although ciga-
rette smoke is a complex mixture, nicotine
is considered the main toxic and addic-
tive compound of tobacco and a clinical risk factor
for atherosclerosis (2–4). Nicotine activates a family
of receptors involved in endogenous cholinergic
signaling pathways (4). Two different types of
nicotinic acetylcholine receptors are distinguished.
Whereas the muscle type promotes synaptic trans-
mission at the motor endplate, the neuronal type—
originally discovered in the nervous system—is also
expressed by several non-neuronal, nonexcitable
cells (5). The presence of neuronal nicotinic acetyl-
choline receptors (nAChRs) at locations unrelated
See page 537
to synaptic activity supports the hypothesis that
acetylcholine may have cellular functions mediated
by nicotinic receptors (5). nAChRs are present on
erve fibers innervating blood vessels, and there is
rowing evidence for an nAChR-mediated direct
ffect of nicotine on the arterial wall (4–6). The
resence of nAChRs in a variety of non-neuronal
ells, unrelated to synaptic activity, suggests that
icotine causes some of its toxic effects in the
espiratory and cardiovascular systems by binding to
AChRs in these organs (5).
Neuronal nAChRs have been shown to assemble as
homogeneous (7-, 9-, and 10-receptors) or
heterogeneous (e.g., 42-receptor) pentamer of - and
-subunits, including 2–7 and 2–4. 7-, 9-, and
10-subunits are also able to assemble in functional
-heteropentamers (4,7–9). The composition of sub-
units determines ligand specificity, ligand affinity,
cation permeability, and channel kinetics (10).
42 nAChRs can be noninvasively visualized with
-18F-Fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine
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ligand with high affinity to 2 subunits (11). [18F]-
2-Fluoro-A85380 is the first radiotracer allowing
subtype-selective investigation of nAChRs in vivo
in humans by using positron emission tomography
(PET) imaging, primarily in the brain (11,12). It
was shown that there is a broad reduction of the
42 nAChR availability in patients with Par-
inson’s disease (PD) without clinically mani-
ested dementia or depression compared with
ealthy volunteers (13). In contrast, in smokers
ithout any neurological or medical disease,
AChRs in the brain were up-regulated com-
ared with nonsmokers (14).
Because of the well-known similarity between
AChRs both within and outside the brain, [18F]-
2-Fluoro-A85380 might also allow in vivo
assessment of nAChRs outside the brain.
This is further supported by the fact that it
seemed feasible to image human cardiac
nAChRs (5,15,16).
The aim of the current study was to evaluate
the feasibility of [18F]-2-Fluoro-A85380 to
image the nicotinic 42 receptor subunits in
he human vasculature. Furthermore, we as-
umed that the vascular uptake patterns of the
adiotracer might be different in patients with
eurodegenerative disorders. Once confirmed
o be feasible for imaging nAChRs in the
essels, [18F]-2-Fluoro-A85380-PET imag-
ng might therefore not only allow for in vivo
ssessment of the receptor distribution in the
asculature of subjects with and without
eurodegenerative disorders but also to
valuate receptor density in the vessels,
s previously seen in the human brain of
mokers (14). The latter could therefore
lso provide insights regarding nAChR-mediated
eleterious effects of nicotine.
; **Department of Nuclear Medicine, RWTH
chael A. Wiener Cardiovascular Institute and
ai School of Medicine, New York, New York;
ision of Cardiovascular Medicine, University of
ing Systems, Philips Research Europe, Aachen,
ermany. Work in this paper was partly supported
upport was also provided by NIH/NHLBI R01
Forschungsgemeinschaft) SP 1226 “Nicotine”
on advisory boards for Boehringer-Ingelheim,
Pharma and has received research funding from
inschaft, National Ataxia Foundation, deutsche
orted that they have no relationships relevant to
uest Editor for this paper.
A B B
A N D
CT
JV
MSA
nACh
recep
PAS
PD
PET
tomog
ROI
SHS
SUV
value
SVC
TBR
ratioany
Mi
t Sin
Div
mag
, G
ial s
che
nd
CB
eme
rep
s G2011, accepted November 28, 2011.R E V I A T I O N S
A C R O N YM S
computed tomography
jugular vein
multiple system atrophy
R nicotinic acetylcholine
tor
percent active segments
Parkinson’s disease
positron emission
raphy
region of interest
single hottest segment
standardized uptake
superior vena cava
target-to-background
n
p
h
o
G
w
A
T
s
o
(
d
r
m
i
o
M
a
t
a
d
r
p
b
a
a
s
A
l
r
(
A
a
T
F
d
t
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 5 2 8 – 3 6
Bucerius et al.
Vascular Nicotinic Acetylcholine Receptor Imaging
530M E T H O D S
Study design. This feasibility study evaluating the
AChR density in human brain and vasculature of
atients with neurodegenerative disorders and
ealthy controls was conducted at the Department
f Nuclear Medicine, University of Bonn (Bonn,
ermany). The local institutional review board as
ell as the federal authorities approved the study.
ll individuals provided written informed consent.
he brain part of the results has been published
eparately (17).
Five healthy volunteers and 6 patients with PD
r multiple system atrophy (MSA) were evaluated
mean age 62.6  9.1 years); none had cardiac
isease. None of the study subjects ever smoked or
eceived cardiovascular medications.
PD or MSA was diagnosed by an experienced
ovement disorder specialist (Dr. Wüllner) accord-
ng to the UK Disease Society Brain Bank criteria
r the MSA consensus criteria (18,19). All PD and
SA patients received combinations of levodopa
nd various dopamine agonists. Four patients addi-
ionally received antidepressants, and 2 received
mantadine. PET imaging was performed in a
efined “off” with the last medication 12 h before
adiopharmaceutical application.
Radiochemistry. [18F]-2-Fluoro-A85380 was pre-
ared as a sterile, apyrogenic solution in phosphate
uffer (pH 7.0) as described previously (11). The
queous [18F]fluoride solution was dried in 3 ml of
acetonitrile, 25 mg (66 mol) of Kryptofix™ K222,
nd 2.8 mg (20 mol) of K2CO3. Two milligrams
(4.3 mol) of 2-trimethylammonium-3-(1-tert-
Figure 1. Whole Body [18F]-2-Fluoro-A85380 PET Image
The whole body [18F]-2-Fluoro-A85380 distribution is shown on cor
phy (CT) as well as on PET-only images. Intense tracer uptake in th
observed.butoxycarbonyl-2(S)-azetidinyl-methoxy)-pyridine
trifluoromethanesulfonate dissolved in 1 ml of di-
methyl sulfoxide were added and heated at 135° C
for 5 min. After dilution with 4 ml of water, the
reaction mixture was passed through an ICH car-
tridge (Alltech ICH, Grace Davison Discovery
Science, Deerfield, Illinois), SepPak QMA car-
tridge (Waters Corporation, Milford, Massachu-
setts), and Sep Pak RP18 cartridge (Waters Cor-
poration). The cartridges were washed with 2 ml of
water, and the intermediate product [18F]-N-
BOC-2F-A85380 was eluted from the C18-
cartridge with 1 ml of ethanol. Cleavage of the
BOC group was performed by adding 1 ml 0.2 M
of hydrochloric acid and simultaneous evaporation
of ethanol. After adding 4 ml of phosphate buffer,
the product [18F]-2F-A85380 was filtrated over a
terile filter (0.2 m) and collected in a sterile vial.
n aliquot was analyzed by using high-performance
iquid chromatography and thin-layer chromatog-
aphy. The specific activity of [18F]-2-Fluoro-
A85380 was determined at the end-of-synthesis to
range from 330 to 820 GBq/mol (8.9 to 22.2
Ci/mol) with a radiochemical purity 95%
11,14).
It has previously been shown that [18F]-2F-
85380 has a rapid clearance from the blood with
low rate (15%) of metabolites at 120 min (14).
he tracer is primarily eliminated renally (12).
igure 1 shows the [18F]-2F-A85380 whole body
istribution.
[18F]-2-Fluoro-A85380-PET/computed tomography
imaging. All subjects underwent PET/computed
omography (CT) scanning (biograph, Siemens
fused positron emission tomography (PET)/computed tomogra-
er, the kidneys, and the bladder as well as in the vertebra isonal
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531Medical Systems, Erlangen, Germany). After ad-
ministration of an intravenous bolus injection of
371.2  58.1 MBq of [18F]-2-Fluoro-A85380, all
patients rested comfortably for 49 to 92 min (74.9 
11.6 min) before acquisition. A whole body
PET/CT scan with 5 to 6 bed positions, each with
3-min acquisition time, was performed. PET was
acquired in 3-dimensional mode using a matrix of
256  256, followed by reconstruction of the data
sing iterative reconstruction. The reconstructed
esolution of the PET system was 6.7 mm. A
ow-dose, noncontrast-enhanced CT imaging pro-
ocol (130 kV, 40 mAs; 2 helical slices, 5-mm slice
hickness) was used, ensuring a diagnostic quality of
he images and providing a reasonable contrast to
elineate and judge the targeted structures such as
he arterial vessel walls and the lumen of the
uperior vena cava (SVC) and both jugular veins
JVs) to assure an appropriate estimation of the
lood pool activity of the tracer. CT images were
econstructed onto a 512  512 matrix, and these
ata, expressed as Hounsfield units, were converted
nto 511 keV equivalent attenuation factors for
ttenuation corrections.
Image analysis. All scans were analyzed in consen-
sus by 2 experienced readers (J.B., C.M.). Image
analysis was performed on an Imalytics Research
Workspace (Imalytics 2.1, Philips Technologies
GmbH Innovative Technologies, Aachen, Ger-
many). Vascular tracer uptake was measured ac-
cording to established methods that have been
published previously (20).
Following a standardized image analysis proto-
col, both carotids, the ascending and descending
aorta, the aortic arch, and both the JV and SVC
were evaluated. For the carotid arteries, only the
common carotid artery up to the bifurcation was
analyzed on both sides of the neck. Slices where the
anatomy of the distinct vessel could not be identi-
fied with certainty were excluded. Arterial [18F]-2-
luoro-A85380 uptake was quantified by drawing a
egion of interest (ROI) around each artery on every
lice of the co-registered transaxial PET/CT images
Fig. 2) (20,21). Next, the maximal arterial stan-
ardized uptake value (SUVmax) was calculated
within the region of interest of every slice of the
vessel. By averaging the maximum SUV values of
all arterial slices of each of the analyzed vessels,
a meanSUVmax value was derived for an individual
essel. The maximal arterial target-to-background
atio (TBRmax) was then calculated by correcting
the SUVmax for blood activity. This was done by
ividing the SUVmax values in a distinct artery bythe average blood SUVmean, estimated from both
JVs (for correcting the carotid arteries) or the SVC
(for correcting the ascending and descending aorta
as well as the aortic arch), respectively. Based on
previously published data on 18F-FDG-PET, this
orrection is considered to be a reflection of arterial
18F]-2-Fluoro-A85380 uptake (20,21). For evalu-
ation of the mean [18F]-2-Fluoro-A85380 blood
ool uptake (mean SUVmean), at least six 3- to
4-mm ROIs were placed in consecutive slices of
both, the JVs or the SVC, and averaged. Corrected
SUVmax values were averaged to derive a meanTBRmax
for all of the analyzed arteries. In addition, we
identified the single hottest segment (SHS), de-
fined as the highest TBRmax value of the arteries as
ell as the percent active segments (PAS) of each
rterial vessel. PAS reflects the percentage of all
egments of a distinct artery above a predefined
hreshold, namely TBRmax 1.32 (ascending
aorta), 1.71 (descending aorta), 1.68 (aortic
arch), and 1.27 (carotids), respectively. These
thresholds were determined by calculating the me-
dian of all meanTBRmax values of the 4 different
Figure 2. [18F]-2-Fluoro-A85380 PET Image Analysis
This ﬁgure shows one slice of the fused PET/CT images of the
neck in transaxial view. Regions of interest (ROIs) drawn
around the outer border of the vessel walls of the left and
right common carotid artery (red ROIs) as well as for evalua-
tion of the [18F]-2-Fluoro-A85380 blood pool activity, within
the lumen of both jugular veins (blue ROIs; maximal stan-
dardized uptake value [SUVmax], SUVmean, and diameter of all
ROIs were evaluated). A higher arterial [18F]-2-Fluoro-A85380
uptake is easily visualizable in the right carotid artery com-
pared with the left carotid artery (SUVmax 1.79 vs. 1.23)
whereas similar SUVmean values are seen for the [
18F]-2-
Fluoro-A85380 blood pool activity in both jugular veins (JV)
(SUVmean right JV: 1.26; SUVmean left JV 1.22). Abbreviations
in Figure 1.arterial territories across all subjects.
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532Statistical analysis. A one-way analysis of variance
ith the appropriate adjustment for multiple com-
arisons was used to test for differences of the
18F]-2-Fluoro-A85380 uptake values between all
vessels in the total study population. Post hoc
analyses were performed using the Tukey test. The
Student t test was performed after confirming
normal distribution to compare [18F]-2-Fluoro-
A85380 uptake values for the arterial territories
altogether as well as for each of the arterial territo-
ries between the group of volunteers and the group
of patients with neurological disorders. After con-
firming normal distribution, Pearson correlation
coefficients (r) were calculated to evaluate a poten-
tial association between the age and the body mass
index of the subjects and the different uptake
parameters.
All statistical analyses were performed using
SPSS version 16.0 (SPSS Inc., Chicago, Illinois).
R E S U L T S
No pharmacological effects (e.g., changes in heart
or respiration rate or blood pressure) were observed
after administration of [18F]-2-Fluoro-A85380. In
he current study, the administered mass doses were
.5 to 1.5 nmol and thus 1% of the dose, which
ed to pharmacological effects in nonhuman pri-
ates (22).
In 2 of 11 subjects, the anatomy of the left carotid
rtery could not be clearly identified on the CT scan
nd was therefore excluded from further analyses.
owever, in each case, the anatomy of the right
arotid artery was assessable and rendered data for
Table 1. Patient Characteristics
Subject Disorder Sex Age (
1 Volunteer M 47
2 Volunteer M 61
3 Volunteer F 66
4 Volunteer M 60
5 Volunteer F 80
Mean SD — — 62.7
6 PD M 70
7 PD F 66
8 PD M 70
9 MSA M 60
10 MSA F 60
11 MSA F 50
Mean SD 62.6
Total mean  SD — — 62.6BMI  body mass index; MSA  multiple system atrophy; NA  not available; PD tatistical analyses of the carotids in both subjects.
atient characteristics are shown in Table 1.
In all subjects, [18F]-2-Fluoro-A85380 uptake in
the arteries as well as in the JV and SVC could be
easily identified by visual inspection. Furthermore,
with the exception of the 2 left carotid arteries as
mentioned earlier, ROIs for semi-quantitative anal-
yses of the [18F]-2-Fluoro-A85380 uptake could be
precisely placed in all analyzed vessels.
No correlation was observed between the 4 [18F]-
-Fluoro-A85380 uptake parameters and the age of
he subjects. Body mass index significantly corre-
ated with the meanSUVmax in the ascending aorta
r  0.81; p  0.004), in the aortic arch (r  0.86;
p  0.001), and in the carotids (r  0.64; p 
0.048), as well as with the meanSUVmean in the JV
r  0.64; p  0.046) and the SVC (r  0.74; p 
0.014).
Differences between the [18F]-2-Fluoro-A85380
ptake of each arterial territory in the total study
opulation are depicted in Figures 3 and 4. Uptake
alues for the arterial territories altogether as well as
or each of the 4 arterial territories in the subgroups
f volunteers and patients with PD or MSA,
espectively, are provided in Table 2. Considering
he total study population, all [18F]-2-Fluoro-
A85380 uptake parameters except the PAS values
were shown to be highest in the descending aorta,
followed by the aortic arch, the ascending aorta, and
the carotids. Statistically significant differences were ob-
served with regard to the meanSUVmax, the meanTBRmax,
nd the SHS values between the descending aorta
nd the ascending aorta as well as the carotids
Fig. 3). In contrast, highest PAS values were
Height (m) Weight (kg) BMI (kg/m2)
1.91 79 21.7
1.88 90 25.5
1.72 62 21.0
1.65 78 28.7
NA 80 NA
1.79 0.13 77.8 10.1 24.2 3.6
1.73 95 31.7
1.73 55 18.4
1.74 82 27.1
1.73 80 26.7
1.60 54 21.1
1.68 60 21.3
1.70 0.05 71.0 17.0 24.4 5.0
1.74 0.09 74.1 14.1 24.3 4.2yrs)
11.6
7.5
9.1Parkinson’s disease.
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533found for the carotids followed by the ascending
and descending aorta and the aortic arch. How-
ever, these differences were not statistically sig-
nificant (Fig. 4).
D I S C U S S I O N
Over the past decade, interest has increased in
noninvasive functional imaging of vascular inflam-
mation or different parts of the underlying complex
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Figure 4. Average PAS Values in Each Arterial Territory
Analyzed
Percent active segments (PAS) are deﬁned as the percentage of
segments with TBRmax 1.32 (AscAorta), 1.71 (DescAorta),
1.68 (AorticArch), and 1.27 (Carotids), respectively. No statis-
tically signiﬁcant differences between the arterial territories were
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Figure 3. Average meanSUVmax, meanTBRmax, and Single Hottest
Comparison of [18F]-2-Fluoro-A85380 uptake values revealed the fo
niﬁcant differences only) between the different arterial territories: m
(AscAorta) p  0.019; DescAorta versus Carotids p  0.0001; Aortic
AscAorta p  0.003; DescAorta versus Carotids p  0.001; Single H
versus Carotids p  0.002. TBR  target-to-background ratio; otherw
seen with regard to PAS. Abbreviations as in Figure 3.pathological processes of atherosclerosis by means
of PET (23).
Imaging of nAChRs in the vasculature might be
a promising approach because the availability of
evidence, which suggests that this type of receptor
can be found in vascular cells such as smooth
muscle, endothelial, or immune cells, including
lymphocytes, monocytes, and platelets (6,24–26).
In the vascular system, 3, 4, 5, 7, and 10
nicotinic subunits were previously found in smooth
muscle cells (5,27). Although the 4-subunit is not
etected in muscle, kidney, or lung arteries, every
nAChR subunit has been detected in the thoracic
aorta except the 9-subunit (4,27). Interestingly,
he 4-subunit was also detected in the abdominal,
ut not ascending, aorta and the pulmonary trunk
4). The 7-nAChR is expressed on a majority of
mooth muscle cells and intrapulmonary arteries
ith the exception of the renal circulation (6,27).
everal lines of evidence show that 3-, 5-, 7-,
10-, and 2–4-subunits are also found on human
vascular endothelial cells (5,24,28). Furthermore,
immunohistochemical staining for nAChRs iso-
forms using nAChR subunit–specific antibodies
revealed 3, 4, 7, 2 and 4 to be expressed by
uman umbilical vein endothelial cells (29). It was
lso found that coronary microvascular endothelial
ells of the rat expressed messenger ribonucleic acid
or the subunits 2, 3, 4, 5, and 7 as well as
2 and 4 of the nAChRs, whereas the 3-subunit
TBRmax
c
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ing statistically signiﬁcant differences (p values are given for sig-
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534shown previously that the deleterious effects of
nicotine, as part of tobacco smoke, on the arterial
wall might be mediated by exactly those nAChRs
(4–6,24–26,28–30). These mediating effects of
nAChRs are related to the control of smooth
muscle cell proliferation and angiogenesis, of endo-
thelial cell proliferation by, among others, inducing
the expression of endothelial growth factors and
up-regulating endothelial nitric oxide synthase in
endothelial cells, invasion, and angiogenesis, as well
as by activation of immune cells such as lympho-
cytes (3,6,24–27,29,31,32).
It was previously shown that smoking up-
regulates 42 nAChRs in the human brain (14).
Table 2. [18F]-2-Fluoro-A85380 Uptake Values of All and Each
of the Different Arterial Territories Between Volunteers and
Patients With PD or MSA, Respectively
[18F]-2-Fluoro-A85380
Uptake Value Volunteers
Patients
(PD  MSA) p Value
All arterial territories
meanSUVmax 1.84 0.39 1.89 0.45 NS
meanTBRmax 1.59 0.24 1.45 0.31 NS
PAS 63.5 31.6 41.6 41.2 NS
SHS 1.84 0.32 1.65 0.46 NS
Ascending aorta
meanSUVmax 1.79 0.29 1.71 0.4 NS
meanTBRmax 1.51 0.14 1.26 0.07 0.003
PAS 81.7 29.1 28.9 30.7 0.017
SHS 1.65 0.19 1.41 0.11 0.025
Descending aorta
meanSUVmax 2.04 0.25 2.29 0.29 NS
meanTBRmax 1.72 0.11 1.76 0.44 NS
PAS 54.1 29.0 48.9 49.5 NS
SHS 2.03 0.12 2.13 0.69 NS
Aortic arch
meanSUVmax 2.07 0.35 2.04 0.39 NS
meanTBRmax 1.74 0.11 1.52 0.15 0.026
PAS 69.1 31.3 24.4 38.1 NS
SHS 2.05 0.16 1.63 0.21 0.005
Carotids
meanSUVmax 1.45 0.36 1.53 0.31 NS
meanTBRmax 1.39 0.34 1.28 0.13 NS
PAS 49.2 35.4 64.4 41.6 NS
SHS 1.62 0.44 1.42 0.14 NS
Values are mean SD. Each of the 4 groups in all arterial territories comprises
1 of the different [18F]-2-Fluoro-A85380 uptake values of all of the 4 different
arterial territories from each patient. Therefore, for each patient, 4 different
values for each uptake parameter from the 4 different territories entered
further analyses. No statistical signiﬁcant differences were found between
both groups of subjects for all of the 4 different [18F]-2-Fluoro-A85380 uptake
values when pooling all of the 4 arterial territories. Comparing each of the
arterial territories between both groups revealed signiﬁcantly lower uptake
parameters in the group of patients with neurological disorders in the
ascending aorta (meanTBRmax, PAS, SHS) and in the aortic arch (meanTBRmax,
SHS). MSA  multiple system atrophy; PAS  percent active segments; PD 
Parkinson’s disease; SHS  single hottest segment; SUVmax  maximal
standardized uptake value; TBR  target-to-background ratio.ranslating these findings to the vasculature by psing noninvasively functional imaging of the
AChRs can provide insights into the pathogenic
ole of nicotine in the atherosclerotic process by
onfirming a higher number of nAChRs in the
essels of smokers. Proving the presence and the
ensity of nAChRs in the vasculature by using
oninvasive functional imaging would provide the
ationale for therapeutic modulation of the afore-
entioned nAChRs-mediated processes, as already
hown in an experimental setting (32). Whereas
AChR antagonists such as mecamylamine were
reviously shown to have anti-angiogenic properties
n an animal model of choroidal neovascularization,
AChR agonist such as choline, in contrast, en-
anced angiogenesis and restored blood flow in rat
odels of myocardial infarction. They may there-
ore facilitate revascularization in ischemic tissues
33,34).
The data of the current study seem to indicate
hat visualization of 42 nAChRs in arterial
essels using [18F]-2-Fluoro-A85380 might be fea-
ible. This result is even more striking because it has
een previously shown that among nAChRs, those
ontaining 4 and 2 subunits, and probably those
subtypes containing 2 in combination with other
subunits, have the highest affinity for nicotine. They
might therefore be among the most important
mediators of the nicotine-related pathogenic impact
on atherosclerosis (16). By correcting the [18F]-2-
luoro-A85380 SUVs for the underlying unspecific
ackground activity, we found the calculated TBRs
till to be higher than the underlying blood pool
18F]-2-Fluoro-A85380 activity. This clearly indi-
cates a specific [18F]-2-Fluoro-A85380 uptake in
the arterial vessel wall, as, in case of unspecific tracer
accumulation, one has to assume a TBR equal to
1. We found the [18F]-2-Fluoro-A85380 uptake
arameters to be highest in the descending aorta.
his is impressive because previous data from an
nimal study by Brüggmann et al. (4) revealed the
ighest distribution of the 4 subunit in vascular
mooth muscle cells distal to the ascending aorta.
ecause [18F]-2-Fluoro-A85380 visualizes 4 and
2 subunits, our data seem to confirm these find-
ings in humans.
[18F]-2-Fluoro-A85380 was recently developed
to noninvasively visualize 42 nAChRs in the
central nervous system. Because of its high affinity
and selectivity to these distinct nAChR subtypes, it
could be proven to be highly suitable for in vivo
assessment of the 42 nAChR availability in the
uman brain (12). It was recently shown that in
atients with Alzheimer’s disease or PD and mild
n
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535cognitive impairment, the availability of the 42
AChRs was decreased (13,35). A reduced avail-
bility of nAChRs in the brain could also be shown
n our patient population when evaluating the tracer
ptake patterns and therefore the nAChR distribu-
ion in the brain. These data were previously pub-
ished by our group (17). We found a significant
eduction of radioactivity intra-individually in the
eft compared with the right temporal cortex. Sim-
larly, we also observed a minor decrease of radio-
ctivity in the putamen of patients with PD and
SA. MSA patients, although of the parkinsonian
ype, showed a significant reduction of [18F]-2-
luoro-A85380 accumulation in the cerebellum
17). Our data seem to be in accordance with the
nding of diminished 42 nAChR availability in
he brain in patients with neurodegenerative disor-
ers; statistically significant differences of the [18F]-
-Fluoro-A85380 uptake between volunteers and
atients with neurological disorders (lower uptake)
ere observed. Because this significant reduction of
he [18F]-2-Fluoro-A85380 uptake was only seen
n 2 of the 4 different arterial territories of the
atients and was not seen at all when pooling the
erritories, our data seem to indicate that different
arts of the vascular system might be differently
ffected by neurodegenerative changes, if at all. The
nding of an altered vascular nAChR density in
atients with neurodegenerative disorders is in-
riguing because the results of the current study
ight also indicate a usefulness of [18F]-2-Fluoro-
85380 vascular imaging to provide insights into
he pathogenesis of PD or Alzheimer’s disease.
his cannot be overemphasized because the vascu-
ar role in the pathologic process of Alzheimer’s
isease became more and more evident over the past
ears, and there has been continuous debate over
he last 75 years about the existence of vascular
arkinsonism as opposed to idiopathic PD (36–38).
ecause the differentiation of vascular parkinsonism
rom idiopathic PD remains a challenge, [18F]-2-ome a possible diagnostic measure for this purpose
n the future (38).
Study limitations. The study population, both of
atients with PD and MSA, respectively, as well as
ealthy volunteers was rather small, and heteroge-
eous limiting to some degree its conclusions.
owever, it was designed as a feasibility study of
rterial nAChR imaging with the recently devel-
ped [18F]-2-Fluoro-A85380 PET tracer. Future
tudies will be needed to confirm the correlation
etween the vascular [18F]-2-Fluoro-A85380 up-
ake and the presence of 42 nAChRs by using
istology. As a further limitation, no dynamic
ascular PET imaging of [18F]-2-Fluoro-A85380
as performed. However, in this feasibility study,
e found an easily and clearly visualizable TBR of
he tracer 70 min after injection. Furthermore,
emi-quantitative analyses of the [18F]-2-Fluoro-
85380 uptake with appropriate correction for the
onspecific background activity of the tracer also
ndicated specific tracer uptake in the arterial ves-
els. Finally, subjects did not have established vas-
ular disease. Therefore, at this time, we cannot
orrelate the tracer uptake in the vessels with
linical cardiovascular risk factors except for body
ass index. This issue will be addressed by future
rials with a dedicated and well-powered study
opulation.
C O N C L U S I O N S
The results of the feasibility study seem to indicate
a specific uptake of [18F]-2-Fluoro-A85380 for in
ivo visualization of 42 nAChRs in human
arterial vessels. Furthermore, vascular [18F]-2-
luoro-A85380 imaging might also provide infor-
ation on the vascular role in neurodegenerative
isorders such as PD or Alzheimer’s disease.
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